Kala Pharmaceuticals ( ($KALA) ) has shared an update. On September 28, 2025, KALA BIO, Inc. announced its decision to cease the development of ...
Kala Bio announced that CHASE (NCT05727878), its phase 2b clinical trial of KPI-012 for persistent corneal epithelial defect ...
Based on the CHASE trial results, KALA plans to cease development of KPI-012 and its mesenchymal stem cell secretome platform. KALA plans to ...
Keep reading to learn about eight KPIs that can help sharpen contingent workforce ROI.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback